Study		Exclusion reasons	Remarks	Reference(s)
CheckMate 511, 2019	randomized controlled trial		phase IIIb/IV
Amaria, 2018	-	inadequate or absent control group		Amaria Nat. Med. 2018; 24:1649-1654 10.1038/s41591-018-0197-1
Hersh, 2011	-	inadequate or absent control group		Hersh Invest New Drugs 2011; 29:489-98 10.1007/s10637-009-9376-8
Wolchok, 2010	-	inadequate or absent control group		Wolchok Lancet Oncol. 2010; 11:155-64 10.1016/S1470-2045(09)70334-1 Wolchok Ann. Oncol. 2013; 24:2174-80 10.1093/annonc/mdt161
Blank, 2018	-	not relevant study design		Blank Nat. Med. 2018; 24:1655-1661 10.1038/s41591-018-0198-0
Long, 2018	-	not relevant study design		Long Lancet Oncol. 2018; 19:672-681 10.1016/S1470-2045(18)30139-6
Lebbé, 2019	-	not relevant outcome		Lebbé J. Clin. Oncol. 2019; 37:867-875 10.1200/JCO.18.01998
OpACIN-neo, 2019	-	not relevant outcome		Rozeman, E.A. The Lancet Oncology 2019; 20:948-. 10.1016/S1470-2045(19)30151-2